Pharmaceuticals News and Research

RSS

New report on current & future trends for big data utilization in biopharmaceutical sector

In recent years, the biopharmaceutical industry has seen an explosion in the availability of Big Data that can generate valuable insights. Despite this, the inherent costs and challenges that come with utilizing Big Data have caused the biopharmaceutical sector to embrace Big Data analytics much slower than other industries.

1 Jun 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

The rapidly emerging field of precision medicine is a "disruptive innovation" that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week's issue of the New England Journal of Medicine.

1 Jun 2015

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

It's a new weapon in the arsenal of cancer fighting treatments: utilizing genetically modified viruses to invade cancer cells and destroy them from the inside.

1 Jun 2015

'Conflict of Interest and Scientific Discovery' symposium to be held at Penn’s Perelman School of Medicine

How can academic medical centers best manage the emerging issue of conflict of interest among scientists and physicians working to develop the next generation of treatments and cures? How do academic conflict of interest policies affect the process of scientific discovery?

1 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

BioDelivery Sciences calls for new treatment options for opioid addiction

As the rate of opioid abuse soars to new levels, growing recognition of the problem is garnering unprecedented media attention—as well as motivating innovative new approaches to better treatment.

30 May 2015

Modified herpes virus improves survival in melanoma patients

University of Louisville researcher Jason Chesney, M.D., Ph.D., deputy director of the James Graham Brown Cancer Center, and a team of international scientists found that stage IIIb to IV melanoma patients treated with a modified cold sore (herpes) virus had improved survival.

30 May 2015

New UAB research shows that HBP medications can increase stroke risk

Untreated high blood pressure, or hypertension, wreaks havoc on the body, leading to heart disease and stroke. New research from the University of Alabama at Birmingham published in the journal Stroke shows that, although HBP medications are beneficial, it is as risky to wait for the condition to develop and then treat it to a controlled level.

30 May 2015

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

The Drugs for Neglected Diseases initiative and four pharmaceutical firms, Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc have announced the start of a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.

30 May 2015

Merck signs in vitro fertilization deal with Genea Biomedx

Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for Assisted Reproductive Treatment (ART), receives global marketing and commercialization rights to Genea Biomedx’s product portfolio.

30 May 2015

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Guardian Research Network, Molecular Health to provide therapeutic clinical trial access to cancer patients

The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

29 May 2015

PDA extends support to Johnson & Johnson Kilmer Conference on sterility assurance and sterilization

The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.

29 May 2015

Pharmaceuticals News and Research

New report on current & future trends for big data utilization in biopharmaceutical sector

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

'Conflict of Interest and Scientific Discovery' symposium to be held at Penn’s Perelman School of Medicine

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

BioDelivery Sciences calls for new treatment options for opioid addiction

Modified herpes virus improves survival in melanoma patients

New UAB research shows that HBP medications can increase stroke risk

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

Merck signs in vitro fertilization deal with Genea Biomedx

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Guardian Research Network, Molecular Health to provide therapeutic clinical trial access to cancer patients

PDA extends support to Johnson & Johnson Kilmer Conference on sterility assurance and sterilization

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring